Terms: = Breast cancer AND CYP2D6, CPD6, CYP2D, CYP2D7AP, CYP2D7BP, CYP2D7P2, CYP2D8P2, CYP2DL1, CYPIID6, P450-DB1, P450C2D, P450DB1 AND Treatment
249 results:
1. Identification of ADME genes polymorphic variants linked to trastuzumab-induced cardiotoxicity in breast cancer patients: Case series of mono-institutional experience.
Staropoli N; Scionti F; Farenza V; Falcone F; Luciano F; Renne M; Di Martino MT; Ciliberto D; Tedesco L; Crispino A; Labanca C; Cucè M; Esposito S; Agapito G; Cannataro M; Tassone P; Tagliaferri P; Arbitrio M
Biomed Pharmacother; 2024 May; 174():116478. PubMed ID: 38547766
[TBL] [Abstract] [Full Text] [Related]
2. In vitro and in vivo pharmacokinetics, disposition, and drug-drug interaction potential of tinengotinib (TT-00420), a promising investigational drug for treatment of cholangiocarcinoma and other solid tumors.
Ni S; Li L; Sun X; Wang Y; Yu Q; Wang W; Gu Z; Yu Z; Wu D; Wu F; Jiang S; Peng P
Eur J Pharm Sci; 2024 Jan; 192():106658. PubMed ID: 38048851
[TBL] [Abstract] [Full Text] [Related]
3. Evaluation of the effect of cyp2d6*3, *4,*10, and *17 polymorphisms on the pharmacokinetic of tamoxifen and its metabolites in patients with hormone-positive breast cancer.
Saghafi F; Salehifar E; Ebrahimi P; Shiran MR; Zaboli E; Sohrevardi SM; Jamialahmadi T; Sahebnasagh A; Sahebkar A
J Pharm Biomed Anal; 2024 Jan; 238():115839. PubMed ID: 37976989
[TBL] [Abstract] [Full Text] [Related]
4.
Ramírez G; Vital M; Vergara C; Carusso F; Neffa F; Valle AD; Esperón P
Per Med; 2023 Nov; 20(6):477-483. PubMed ID: 37947089
[No Abstract] [Full Text] [Related]
5. Design, synthesis, and in-silico study of novel triarylethylene analogs with dual anti-estrogenic and serotonergic activity.
Mostafa T; Albeir M; Wober J; Abadi A; Salama I; Ahmed NS
Drug Dev Res; 2024 Feb; 85(1):e22127. PubMed ID: 37877739
[TBL] [Abstract] [Full Text] [Related]
6. Tamoxifen pharmacokinetics and pharmacodynamics in older patients with non-metastatic breast cancer.
Souwer ETD; Sanchez-Spitman A; Moes DJAR; Gelderblom H; Swen JJ; Portielje JEA; Guchelaar HJ; van Gelder T
Breast Cancer Res Treat; 2023 Jun; 199(3):471-478. PubMed ID: 37067610
[TBL] [Abstract] [Full Text] [Related]
7. Effects of Genetic Polymorphisms of Drug Metabolizing Enzymes and co-Medications on Tamoxifen Metabolism in Black South African Women with breast cancer.
Chiwambutsa SM; Ayeni O; Kapungu N; Kanji C; Thelingwani R; Chen WC; Mokone DH; O'Neil DS; Neugut AI; Jacobson JS; Ruff P; Cubasch H; Joffe M; Masimirembwa C
Clin Pharmacol Ther; 2023 Jul; 114(1):127-136. PubMed ID: 37042388
[TBL] [Abstract] [Full Text] [Related]
8. Early increase in tamoxifen dose in cyp2d6 poor metaboliser breast cancer patients and survival: A propensity score matching analysis.
Blancas I; Linares-Rodríguez M; Martínez de Dueñas E; Herrero-Vicent C; Molero-Mir MD; Garrido JM; Rodríguez-Serrano F
Breast; 2023 Jun; 69():342-348. PubMed ID: 37011481
[TBL] [Abstract] [Full Text] [Related]
9. Adherence to endocrine therapy in early breast cancer in relation to Cytochrome P450 2D6 genotype: a comparison between pharmacy dispensation data and medical records.
Thorén L; Margolin S; Eliasson E; Bergh J; Lindh JD
Breast Cancer Res Treat; 2023 Apr; 198(3):499-508. PubMed ID: 36856936
[TBL] [Abstract] [Full Text] [Related]
10. Toward model-informed precision dosing for tamoxifen: A population-pharmacokinetic model with a continuous cyp2d6 activity scale.
Agema BC; Buijs SM; Sassen SDT; Mürdter TE; Schwab M; Koch BCP; Jager A; van Schaik RHN; Mathijssen RHJ; Koolen SLW
Biomed Pharmacother; 2023 Apr; 160():114369. PubMed ID: 36753957
[TBL] [Abstract] [Full Text] [Related]
11. Genetic Polymorphisms of Cytochromes P450 in Finno-Permic Populations of Russia.
Dzhaubermezov M; Ekomasova N; Mustafin R; Gabidullina L; Galimova Y; Nurgalieva A; Valova Y; Prokofyeva D; Khusnutdinova E
Genes (Basel); 2022 Dec; 13(12):. PubMed ID: 36553620
[TBL] [Abstract] [Full Text] [Related]
12. Design, synthesis, and metabolite identification of Tamoxifen esterase-activatable prodrugs.
Elbagoury RM; Shenouda MA; Elnakib HE; Wober J; Abadi AH; Ahmed NS
Bioorg Chem; 2023 Feb; 131():106303. PubMed ID: 36455483
[TBL] [Abstract] [Full Text] [Related]
13. Pharmacogenetics as a predictor chemotherapy induced peripheral neuropathy in gynecologic cancer patients treated with Taxane-based chemotherapy.
Mysona D; Dorr K; Ward A; Shaver E; Rungruang B; Ghamande S
Gynecol Oncol; 2023 Jan; 168():114-118. PubMed ID: 36434945
[TBL] [Abstract] [Full Text] [Related]
14. Bioavailability and Pharmacokinetics of Endoxifen in Female Rats and Dogs: Evidence to Support the Use of Endoxifen to Overcome the Limitations of cyp2d6-Mediated Tamoxifen Metabolism.
Koubek EJ; Buhrow SA; Safgren SL; Jia L; Goetz MP; Ames MM; Reid JM
Drug Metab Dispos; 2023 Feb; 51(2):183-192. PubMed ID: 36351835
[TBL] [Abstract] [Full Text] [Related]
15. The frequencies of cyp2d6 alleles and their impact on clinical outcomes of adjuvant tamoxifen therapy in Syrian breast cancer patients.
Ismail Al-Khalil W; Al-Salhi L; Rijjal S; Aljamali M; Youssef LA
BMC Cancer; 2022 Oct; 22(1):1067. PubMed ID: 36243690
[TBL] [Abstract] [Full Text] [Related]
16. Factors affecting inter-individual variability in endoxifen concentrations in patients with breast cancer: results from the prospective TOTAM trial.
Braal CL; Westenberg JD; Buijs SM; Abrams S; Mulder TAM; van Schaik RHN; Koolen SLW; Jager A; Mathijssen RHJ
Breast Cancer Res Treat; 2022 Aug; 195(1):65-74. PubMed ID: 35842520
[TBL] [Abstract] [Full Text] [Related]
17. Identification of novel natural inhibitors targeting AKT Serine/Threonine Kinase 1 (AKT1) by computational study.
Zhong S; Zhang Z; Guo Z; Yang W; Dou G; Lv X; Wang X; Ge J; Wu B; Pan X; Wang H; Mou Y
Bioengineered; 2022 May; 13(5):12003-12020. PubMed ID: 35603567
[TBL] [Abstract] [Full Text] [Related]
18. Results of the implementation of a pharmacogenomics platform based on NGS technologies. Combining clinical and research approaches.
Ramudo-Cela L; Busto-Fernández F; Outeda-Macías M; Antolín S; Calvo-Martínez L; Martín-Herranz I
Farm Hosp; 2021 Dec; 45(7):11-37. PubMed ID: 35379108
[TBL] [Abstract] [Full Text] [Related]
19. Flexible Etherified and Esterified Triphenylethylene Derivatives and Their Evaluation on ER-positive and Triple-Negative breast cancer Cell Lines.
Hassan AS; Wober J; Vollmer G; Abadi AH; Ahmed NS
ChemMedChem; 2022 Apr; 17(7):e202100720. PubMed ID: 35076180
[TBL] [Abstract] [Full Text] [Related]
20. Association between genetic polymorphisms in cytochrome P450 enzymes and survivals in women with breast cancer receiving adjuvant endocrine therapy: a systematic review and meta-analysis.
Chan CWH; Li C; Xiao EJ; Li M; Phiri PGM; Yan T; Chan JYW
Expert Rev Mol Med; 2022 Jan; 24():e1. PubMed ID: 34991754
[TBL] [Abstract] [Full Text] [Related]
[Next]
